查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1992957

DNA疫苗市場：2026-2032年全球市場預測（依技術平台、遞送方式、給藥途徑、研發階段、應用及最終用戶分類）

DNA Vaccine Market by Technology Platform, Delivery Method, Administration Route, Development Stage, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

DNA疫苗市場預計到2025年價值為3.4445億美元，到2026年成長至3.9386億美元，到2032年達到8.6867億美元，複合年成長率為14.12%。

主要市場統計數據
基準年 2025 3.4445億美元
預計年份：2026年 3.9386億美元
預測年份 2032 8.6867億美元
複合年成長率 (%) 14.12%

引言概述了正在重塑全球 DNA 疫苗開發的新科學勢頭、遞送技術創新和戰略意義。

在核酸療法和遞送技術進步的推動下，DNA疫苗的科學和商業性發展正進入一個更嚴格檢驗和選擇性開發的階段。歷史上，DNA疫苗因其理論優勢（例如熱穩定性、易於設計以及能夠編碼複雜抗原）而備受重視，但由於遞送效率低和人體免疫抗原性不足，其廣泛應用受到限制。然而，近年來質體工程、線性及微環DNA平台以及對先天免疫調控機制更深入理解方面的進展，重新激發了研發人員、資助者和臨床研究人員的興趣。

技術、臨床策略和相關人員行為的變革性變化將加速DNA疫苗的實際應用和策略合作。

DNA疫苗領域經歷了翻天覆地的變化，這主要歸因於三個密切相關的因素：技術進步、臨床檢驗趨勢以及相關人員不斷變化的期望。分子支架和載體設計的進步拓展了能夠在體內可靠表達的抗原構建體的種類，而線性DNA和微環平台的出現則為研發人員在表達效率和生產便捷性之間提供了新的權衡方案。同時，電穿孔和脂質聚合物奈米顆粒等遞送方法的改進顯著降低了傳統上有效活化免疫反應的障礙。

2025 年關稅趨勢和貿易政策調整的變化將如何影響供應鏈策略、採購重點和製造在地化方面的決策？

2025年關稅調整和貿易政策調整的累積影響，進一步加劇了支持DNA疫苗研發和生產的全球供應鏈的複雜性。質體和線性DNA生產的關鍵原料——特殊酵素、層析法樹脂、一次性生物製程組件和試劑級耗材——極易受到跨境成本波動的影響。隨著關稅增加投入成本和採購不確定性，疫苗研發機構和合約開發與生產組織（CDMO）正透過重新審視其籌資策略、擴大庫存緩衝以及與本地供應商建立合作關係來應對，以穩定前置作業時間。

關鍵細分洞察揭示了應用重點、平台選擇、劑量、臨床階段和最終用戶趨勢如何影響專案策略和商業化計劃。

基於細分市場的洞察揭示了每種適應症、技術平台、給藥方法、給藥途徑、研發階段和最終用戶的不同開發路徑和商業性考慮。從適應症角度來看，針對感染疾病（感染疾病為細菌、寄生蟲和病毒感染疾病）的項目往往強調快速誘導免疫、低溫運輸和可擴展性，而專注於骨髓惡性腫瘤和固體癌的腫瘤項目則優先考慮抗原特異性、聯合免疫療法策略和腫瘤微環境的調控。平台選擇（線性DNA、微環DNA或質體DNA）會影響人們對生產複雜性、有效載荷能力和基因組安全性的認知，進而影響監管溝通和合作夥伴的選擇。

提供可操作的區域性見解，解釋美洲、歐洲、中東和非洲以及亞太地區在法規、製造業和醫療保健系統方面的差異如何影響專案策略。

鑑於法律規範、醫療基礎設施和生產能力的差異，區域觀點影響各個市場開發商和投資者的策略重點。在美洲，強大的資本市場和以創新為導向的法規環境有利於早期臨床試驗和官民合作關係，而集中的製造群支持快速規模化生產和垂直整合的供應鏈。相較之下，歐洲、中東和非洲（EMEA）的環境則較為複雜，監管協調的努力與不同的准入途徑和採購機制並存，這要求申辦方制定靈活的臨床開發計劃和與支付方的溝通策略，以適應當地的報銷慣例。

從企業層面提供關鍵見解，解釋平台開發商、臨床階段生物技術公司、主要製藥合作夥伴和 CDMO 如何合作加速 DNA 疫苗的進展。

DNA疫苗領域的企業組成既有競爭又有合作，包括專業平台開發公司、臨床階段生物技術公司、大型製藥合作夥伴以及契約製造組織（CDMO）。平台開發公司透過分子設計、專有遞送佐劑或旨在降低生產成本和提高表達效率的生產流程創新來脫穎而出。臨床階段生物技術公司通常專注於特定適應症，並利用獨特的免疫學特徵和生物標記組合來加速概念驗證（PoC）。而大型製藥企業則傾向於尋求策略聯盟和許可，以補充其現有的疫苗產品組合和分銷能力。

為行業領導者提供實用建議，以優先考慮交付技術創新、供應鏈韌性、監管策略、合作夥伴關係和個人化商業化策略。

產業領導者可以採取一系列實際有效的措施來降低風險，同時加速研發和商業化進程。首先，優先投資於能夠顯著改善抗原表達和提高患者耐受性的遞送技術和給藥途徑，並使這些投資與目標適應症的特性和最終用戶的需求相匹配。其次，透過認證多家供應商、探索區域製造夥伴關係關係以及將關稅和貿易應急計劃納入籌資策略，增強供應鏈韌性，以避免專案中斷並確保按計劃進行。

本研究調查方法闡述了支持這些發現的綜合方法，包括綜合文獻分析、監管審查、專家訪談和供應鏈分析。

這項高階主管級分析所依據的研究結合了對同儕審查文獻、臨床試驗註冊資訊、監管指導文件和公開技術報告的系統性回顧，以及有針對性的專家訪談。研究對科學和臨床發現進行了交叉檢驗，以確保臨床前檢驗、劑量表現和臨床開發模式的一致性。透過分析近期關稅表、官方貿易公告和供應鏈中斷案例研究，評估了貿易和政策的影響，重點在於採購和生產決策如何即時調整。

綜合考慮技術進步、營運要求和區域因素，這些因素共同決定了DNA疫苗產生影響的路徑。

總之，DNA疫苗正從主要停留在理論層面，逐步成為現代免疫療法和預防策略的實際應用要素。平台工程的進步，以及給藥方法和實踐的顯著改進，正在擴大DNA疫苗的適應症範圍，使其更具競爭力。同時，貿易政策趨勢和區域環境的差異等外部因素，也要求在生產、採購和打入市場策略進行週詳的規劃。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：依技術平台分類的DNA疫苗市場

  • 線性DNA
  • 迷你環狀DNA
  • 質體DNA

第9章：DNA疫苗市場：依遞送方式分類

  • 電穿孔
  • 基因槍
  • 奈米顆粒遞送
  • 針頭注射

第10章：DNA疫苗市場依給藥途徑分類的分佈

  • 皮內注射
  • 肌肉內部
  • 鼻腔
  • 皮下

第11章：DNA疫苗市場依研發階段分類

  • I期臨床試驗
  • 二期臨床試驗
  • III期臨床試驗
  • 商業的
  • 臨床前

第12章：DNA疫苗市場：依應用領域分類

  • 感染疾病
    • 細菌感染疾病
    • 寄生蟲病
    • 病毒感染疾病
  • 腫瘤學
    • 骨髓惡性腫瘤
    • 固體癌

第13章：DNA疫苗市場：依最終用戶分類

  • 診所
  • 醫院
  • 研究機構

第14章 DNA疫苗市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：DNA疫苗市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 DNA疫苗市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國DNA疫苗市場

第18章：中國DNA疫苗市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Aura Health
  • Breethe
  • Buddhify
  • Calm
  • Chopra Center
  • Gaia
  • Glo
  • Headspace
  • Inner Explorer
  • Inscape
  • Insight Network
  • Inward
  • MEDITOPIA
  • Mindfulness Everywhere
  • MOBIO INTERACTIVE
  • Muse
  • Omvana
  • Pacifica
  • Sattva
  • Simple Habit
  • Smiling Mind
  • WAKING UP
Product Code: MRR-1A1A064C0154

The DNA Vaccine Market was valued at USD 344.45 million in 2025 and is projected to grow to USD 393.86 million in 2026, with a CAGR of 14.12%, reaching USD 868.67 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 344.45 million
Estimated Year [2026] USD 393.86 million
Forecast Year [2032] USD 868.67 million
CAGR (%) 14.12%

Introduction framing the renewed scientific momentum, delivery innovations, and strategic implications that are reshaping DNA vaccine development globally

The scientific and commercial narrative for DNA vaccines has entered a phase of intensified scrutiny and selective momentum, prompted by broader nucleic acid therapy progress and refined delivery science. Historically, DNA vaccines were celebrated for their theoretical advantages-thermostability, ease of design, and capacity to encode complex antigens-but adoption was constrained by delivery inefficiencies and suboptimal immunogenicity in humans. Recent advances in plasmid engineering, linear and minicircle DNA platforms, and a more nuanced understanding of innate immune modulation have reignited interest among developers, funders, and clinical investigators.

Consequently, technology maturation is converging with pragmatic clinical strategy. Electroporation and nanoparticle-based carriers are demonstrating improved antigen expression and immune priming in trial settings, and intradermal and intramuscular administration routes are being optimized to balance safety with immunologic potency. On the regulatory front, clearer guidance on vector characterization and manufacturing controls is facilitating more predictable development pathways. Taken together, these dynamics are reshaping the risk calculus for both established biologics companies and nimble biotech entrants, creating an environment in which strategic partnerships, targeted investments in delivery technologies, and curated clinical programs are central to realizing the long-promised utility of DNA vaccines.

Transformative shifts in technologies, clinical strategies, and stakeholder behavior that are accelerating DNA vaccine viability and strategic collaboration

The DNA vaccine landscape has experienced transformative shifts driven by three interlocking forces: technological refinement, clinical validation trends, and evolving stakeholder expectations. Advances in molecular scaffolding and vector design have expanded the repertoire of antigen constructs that can be reliably expressed in vivo, and the emergence of linear DNA and minicircle platforms is offering developers alternative trade-offs in expression efficiency and manufacturing simplicity. In parallel, improvements in delivery modalities such as electroporation and lipid- or polymer-based nanoparticles are materially reducing prior barriers to robust immune activation.

Clinical development strategies have also shifted toward combination approaches that pair DNA vaccines with adjuvants, heterologous prime-boost regimens, or checkpoint modulators in oncology. As a result, trial designs are increasingly adaptive and biomarker-driven, with a heavier emphasis on correlates of protection and immune durability. Moreover, the competitive landscape is adapting: long-term players are recalibrating portfolios to incorporate DNA vaccines where they complement existing modalities, while smaller innovators are focusing on niche indications or platform differentiation. These shifts collectively push the field toward pragmatic collaboration, targeted regulatory engagement, and selective capital deployment that prioritize demonstrable clinical value and manufacturable delivery solutions.

How evolving tariff dynamics and trade policy adjustments in 2025 are reshaping supply-chain strategies, procurement priorities, and manufacturing localization decisions

The cumulative impact of tariff changes and trade policy adjustments in 2025 has introduced additional complexity into global supply chains that underpin DNA vaccine development and production. Raw materials critical to plasmid and linear DNA production-specialized enzymes, chromatography resins, single-use bioprocess components, and reagent-grade consumables-are sensitive to cross-border cost fluctuations. Where tariffs have increased input prices or created greater procurement uncertainty, sponsors and contract development and manufacturing organizations have responded by reassessing sourcing strategies, extending inventory buffers, and pursuing localized supplier relationships to stabilize lead times.

These adjustments have practical downstream effects on program timelines and contracting practices. Developers are prioritizing dual-sourcing strategies, qualifying domestic manufacturing partners where feasible, and incorporating tariff contingencies into procurement contracts and milestone planning. Regulatory engagement has become more prominent as companies navigate import documentation, classification disputes, and compliance with evolving trade policies. At the same time, the trade environment has prompted more deliberate capital allocation toward regional manufacturing capabilities and supply-chain resilience initiatives, particularly for entities that view long-term commercial supply as a strategic differentiator rather than a short-term cost issue.

Key segmentation insights illuminating how application focus, platform choice, delivery modality, clinical stage, and end-user dynamics inform program strategy and commercialization planning

Segmentation-driven insights reveal distinct development pathways and commercial considerations across applications, technology platforms, delivery methods, administration routes, development stages, and end users. On the application axis, programs targeting infectious diseases-subdivided into bacterial infections, parasitic diseases, and viral infections-tend to emphasize rapid immune induction, cold-chain resilience, and scalability, while oncology programs focusing on hematological malignancies and solid tumors prioritize antigen specificity, combination immunotherapy strategies, and tumor microenvironment modulation. Platform selection-whether linear DNA, minicircle DNA, or plasmid DNA-shapes manufacturing complexity, payload capacity, and perceptions of genomic safety, influencing both regulatory dialogue and partner selection.

Delivery modalities exert a decisive influence on clinical strategy and patient experience. Electroporation has proven effective for enhancing transfection rates and is commonly paired with intramuscular or intradermal administration to maximize antigen expression, while gene gun approaches and nanoparticle delivery are being optimized to improve tolerability and enable mucosal routes such as intranasal delivery. Needle injection remains a pragmatic option in many clinical settings. Development stage segmentation, which spans preclinical to clinical phases I through III and commercial readiness, dictates different evidence requirements, investment profiles, and partnership models. Finally, the end-user landscape-comprising clinics, hospitals, and research institutions-drives considerations around ease of administration, on-site infrastructure needs, and training requirements, factors that are particularly salient when planning rollouts or pilot implementation studies.

Actionable regional insights that explain how regulatory, manufacturing, and healthcare system differences across the Americas, Europe Middle East & Africa, and Asia-Pacific direct program strategies

Regional perspectives shape strategic priorities for developers and investors across markets with differing regulatory frameworks, healthcare infrastructure, and manufacturing capacity. In the Americas, strong capital markets and an innovation-oriented regulatory environment encourage early-stage trials and public-private partnerships, while concentrated manufacturing clusters support rapid scale-up capabilities and vertically integrated supply chains. Conversely, Europe, Middle East & Africa presents a heterogeneous landscape where regulatory harmonization efforts coexist with varied access pathways and procurement mechanisms, prompting sponsors to adopt flexible clinical development plans and payer engagement strategies that reflect local reimbursement realities.

The Asia-Pacific region is characterized by dense manufacturing infrastructure, growing biotech ecosystems, and high-priority public health agendas that favor expedited adoption for vaccines demonstrating clear benefit. These regional attributes influence decisions about clinical trial localization, licensing strategies, and manufacturing siting. As a result, stakeholders are increasingly adopting regionally tailored approaches that align trial designs, regulatory submissions, and market access plans with local norms while preserving global program coherence. Transitioning smoothly across regions requires early cross-jurisdictional regulatory planning and strategic partnerships that can bridge technical, logistical, and policy gaps.

Critical company-level insights describing how platform innovators, clinical biotechs, large pharma partners, and CDMOs are aligning capabilities to accelerate DNA vaccine progress

The competitive and collaborative makeup of companies active in the DNA vaccine space spans specialist platform developers, clinical-stage biotechs, large pharmaceutical partners, and contract manufacturing organizations. Platform developers are differentiating through molecular design, proprietary delivery adjuncts, or manufacturing process innovations intended to reduce cost of goods and improve expression efficiency. Clinical-stage biotechs often focus on narrowly defined indications where a differentiated immunologic profile or compendium of biomarkers can accelerate proof-of-concept, while larger pharmaceutical firms tend to pursue strategic alliances or licensing arrangements to complement existing vaccine portfolios and distribution capabilities.

Contract development and manufacturing organizations play a pivotal role by offering scale, regulatory experience, and process optimization services that de-risk late-stage programs. Academic institutions and translational research centers also contribute through early-stage validation, platform refinement, and investigator-initiated trials. Across these organizational types, successful players balance technical depth with commercial pragmatism, invest in delivery and administration innovations, and cultivate regulatory engagement to smooth path-to-market barriers. Strategic collaborations that bring together complementary capabilities-such as combining a novel platform with an experienced clinical development partner and a CDMO capable of GMP supply-are increasingly the dominant route to de-risked advancement and broader clinical adoption.

Actionable recommendations for industry leaders to prioritize delivery innovation, supply-chain resilience, regulatory strategy, collaborative partnerships, and tailored commercialization playbooks

Industry leaders can adopt a set of pragmatic, high-impact actions to accelerate development and commercial readiness while mitigating risk. First, prioritize investment in delivery technologies and administration pathways that demonstrate reproducible improvements in antigen expression and patient tolerability, aligning these investments with target indication characteristics and end-user needs. Second, strengthen supply-chain resilience by qualifying multiple suppliers, exploring regional manufacturing partnerships, and embedding tariff and trade contingencies into procurement strategies to avoid program interruptions and protect timelines.

Third, pursue modular regulatory engagement and adaptive clinical designs that emphasize biomarker-driven endpoints and immune correlates, thereby reducing uncertainty and enabling faster go/no-go decisions. Fourth, cultivate cross-sector collaborations that pair molecular platform expertise with clinical development capability and scalable manufacturing to create end-to-end value chains. Finally, develop tailored commercialization playbooks that reflect regional regulatory norms, reimbursement pathways, and infrastructure constraints, and invest in training and administration support to ensure smooth deployment in clinics and hospitals. Together these actions create a defensible pathway from proof-of-concept through sustainable market access.

Research methodology describing the integrated approach of literature synthesis, regulatory review, expert consultations, and supply-chain analysis that underpins the findings

The research underlying this executive-level analysis combined a structured review of peer-reviewed literature, clinical trial registries, regulatory guidance documents, and publicly available technical reports with targeted expert consultations. Scientific and clinical inputs were triangulated to ensure consistency across preclinical validation, delivery modality performance, and clinical development patterns. Trade and policy impacts were assessed through analysis of recent tariff schedules, public trade notices, and supply-chain disruption case studies, with attention to how procurement and manufacturing decisions are adapting in real time.

Qualitative interviews with developers, contract manufacturers, clinical investigators, and regulatory advisors provided context on operational bottlenecks, technology adoption drivers, and preferred partnership archetypes. Throughout the study, findings were cross-checked for technical accuracy and relevance, and conclusions emphasized actionable implications over speculative forecasting. The methodological approach prioritized transparency, reproducibility, and the integration of technical, clinical, and commercial perspectives to produce a synthesis that supports strategic decision-making across stakeholders engaged in the DNA vaccine ecosystem.

Conclusion synthesizing technological progress, operational imperatives, and regional considerations that collectively define the path to DNA vaccine impact

In conclusion, DNA vaccines are transitioning from a primarily theoretical promise to a pragmatic element of contemporary immunotherapy and prophylactic strategies. Advances in platform engineering, coupled with meaningful improvements in delivery methods and administration practices, are expanding the set of indications where DNA vaccines can be competitively positioned. At the same time, external factors such as trade policy dynamics and diverse regional environments require deliberate planning around manufacturing, sourcing, and market-entry strategies.

For stakeholders, success depends on aligning scientific differentiation with operational excellence and regulatory foresight. Those who invest early in delivery optimization, supply-chain resilience, and collaborative partnership models will be positioned to convert technical promise into clinical impact and, ultimately, sustainable adoption. The pathway forward emphasizes targeted, evidence-driven development programs that are regionally informed and operationally pragmatic, enabling DNA vaccines to play a meaningful role in both infectious disease control and oncology care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. DNA Vaccine Market, by Technology Platform

  • 8.1. Linear DNA
  • 8.2. Minicircle DNA
  • 8.3. Plasmid DNA

9. DNA Vaccine Market, by Delivery Method

  • 9.1. Electroporation
  • 9.2. Gene Gun
  • 9.3. Nanoparticle Delivery
  • 9.4. Needle Injection

10. DNA Vaccine Market, by Administration Route

  • 10.1. Intradermal
  • 10.2. Intramuscular
  • 10.3. Intranasal
  • 10.4. Subcutaneous

11. DNA Vaccine Market, by Development Stage

  • 11.1. Clinical Phase I
  • 11.2. Clinical Phase II
  • 11.3. Clinical Phase III
  • 11.4. Commercial
  • 11.5. Preclinical

12. DNA Vaccine Market, by Application

  • 12.1. Infectious Diseases
    • 12.1.1. Bacterial Infections
    • 12.1.2. Parasitic Diseases
    • 12.1.3. Viral Infections
  • 12.2. Oncology
    • 12.2.1. Hematological Malignancies
    • 12.2.2. Solid Tumors

13. DNA Vaccine Market, by End User

  • 13.1. Clinics
  • 13.2. Hospitals
  • 13.3. Research Institutions

14. DNA Vaccine Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. DNA Vaccine Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. DNA Vaccine Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States DNA Vaccine Market

18. China DNA Vaccine Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Aura Health
  • 19.6. Breethe
  • 19.7. Buddhify
  • 19.8. Calm
  • 19.9. Chopra Center
  • 19.10. Gaia
  • 19.11. Glo
  • 19.12. Headspace
  • 19.13. Inner Explorer
  • 19.14. Inscape
  • 19.15. Insight Network
  • 19.16. Inward
  • 19.17. MEDITOPIA
  • 19.18. Mindfulness Everywhere
  • 19.19. MOBIO INTERACTIVE
  • 19.20. Muse
  • 19.21. Omvana
  • 19.22. Pacifica
  • 19.23. Sattva
  • 19.24. Simple Habit
  • 19.25. Smiling Mind
  • 19.26. WAKING UP

LIST OF FIGURES

  • FIGURE 1. GLOBAL DNA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DNA VACCINE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DNA VACCINE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DNA VACCINE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DNA VACCINE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DNA VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL DNA VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DNA VACCINE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES DNA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA DNA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DNA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DNA VACCINE MARKET SIZE, BY LINEAR DNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DNA VACCINE MARKET SIZE, BY LINEAR DNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DNA VACCINE MARKET SIZE, BY LINEAR DNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DNA VACCINE MARKET SIZE, BY MINICIRCLE DNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DNA VACCINE MARKET SIZE, BY MINICIRCLE DNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DNA VACCINE MARKET SIZE, BY MINICIRCLE DNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DNA VACCINE MARKET SIZE, BY PLASMID DNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DNA VACCINE MARKET SIZE, BY PLASMID DNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DNA VACCINE MARKET SIZE, BY PLASMID DNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DNA VACCINE MARKET SIZE, BY ELECTROPORATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DNA VACCINE MARKET SIZE, BY ELECTROPORATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DNA VACCINE MARKET SIZE, BY ELECTROPORATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DNA VACCINE MARKET SIZE, BY GENE GUN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DNA VACCINE MARKET SIZE, BY GENE GUN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DNA VACCINE MARKET SIZE, BY GENE GUN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DNA VACCINE MARKET SIZE, BY NANOPARTICLE DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DNA VACCINE MARKET SIZE, BY NANOPARTICLE DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DNA VACCINE MARKET SIZE, BY NANOPARTICLE DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DNA VACCINE MARKET SIZE, BY NEEDLE INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DNA VACCINE MARKET SIZE, BY NEEDLE INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DNA VACCINE MARKET SIZE, BY NEEDLE INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DNA VACCINE MARKET SIZE, BY INTRADERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DNA VACCINE MARKET SIZE, BY INTRADERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DNA VACCINE MARKET SIZE, BY INTRADERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DNA VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DNA VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DNA VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DNA VACCINE MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DNA VACCINE MARKET SIZE, BY INTRANASAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DNA VACCINE MARKET SIZE, BY INTRANASAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DNA VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DNA VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DNA VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICAL PHASE I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICAL PHASE I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICAL PHASE I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICAL PHASE II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICAL PHASE II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICAL PHASE II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICAL PHASE III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICAL PHASE III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICAL PHASE III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DNA VACCINE MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DNA VACCINE MARKET SIZE, BY COMMERCIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DNA VACCINE MARKET SIZE, BY COMMERCIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DNA VACCINE MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DNA VACCINE MARKET SIZE, BY PRECLINICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DNA VACCINE MARKET SIZE, BY PRECLINICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DNA VACCINE MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DNA VACCINE MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DNA VACCINE MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DNA VACCINE MARKET SIZE, BY PARASITIC DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DNA VACCINE MARKET SIZE, BY PARASITIC DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DNA VACCINE MARKET SIZE, BY PARASITIC DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL DNA VACCINE MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL DNA VACCINE MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL DNA VACCINE MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL DNA VACCINE MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL DNA VACCINE MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL DNA VACCINE MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL DNA VACCINE MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL DNA VACCINE MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL DNA VACCINE MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL DNA VACCINE MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL DNA VACCINE MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL DNA VACCINE MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL DNA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL DNA VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL DNA VACCINE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL DNA VACCINE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL DNA VACCINE MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL DNA VACCINE MARKET SIZE, BY RESEARCH INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL DNA VACCINE MARKET SIZE, BY RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL DNA VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS DNA VACCINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS DNA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA DNA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA DNA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA DNA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA DNA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE DNA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE DNA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST DNA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST DNA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA DNA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA DNA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL DNA VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN DNA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN DNA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. GCC DNA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GCC DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 173. GCC DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 174. GCC DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 175. GCC DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 176. GCC DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 177. GCC DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 178. GCC DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 179. GCC DNA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION DNA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION DNA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS DNA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS DNA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. G7 DNA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. G7 DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 200. G7 DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 201. G7 DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 202. G7 DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 203. G7 DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 204. G7 DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 205. G7 DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 206. G7 DNA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. NATO DNA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. NATO DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 209. NATO DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 210. NATO DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 211. NATO DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 212. NATO DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 213. NATO DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 214. NATO DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 215. NATO DNA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL DNA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES DNA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES DNA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA DNA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 229. CHINA DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 232. CHINA DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA DNA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)